

Lyka Labs announces Q2FY17 Financial Results

Revenues at INR 3290.02 Lacs
EBIDTA at INR 786.81 Lacs

Mumbai, 5th November, 2016: Lyka Labs Limited, a pharmaceutical company with business across 55 countries globally in super specialty segments of Injections and Dermatology today announced its Financial Results for the Quarter ended 30th September 2016.

Financial Analysis

Q2FY17 (Quarter Ended 30th September 2016) – Consolidated

- Revenue was at INR **3290.02 Lacs**
- Gross Contribution Margin at **55.17%**
- EBIDTA was INR 786.81 Lacs at **23.92%**
- Net Profit was at **INR 98.36 Lacs** at 2.99%

Business Review and Strategy

- Revenues up by **55.34%** (Q1FY17) and **12.68%*** in Quarter Ended 30th September 2015.
- **EBITDA Margin at 23.92%** against 12.41% in Q1FY17.
- **PAT of INR 98.36 Lacs** against loss of INR 415.91 Lacs in Q1FY17, and loss of INR 235.84* Lacs in Quarter Ended 30th September 2015.
- There has been an overall rise in demand for the Company's products, leading to higher sales.
- Company's recent launch on Dermatology Sales Division is seeing acceptance with the Medical Fraternity.
- Going forward the company will continue its focus on the Global Product Registrations for this Injections and Topical Preparations.
- The company continues to focus on R&D for NDDS, and expects to launch 2 Formulations, through its licensing partner, over the next 6 months.

**Lyka's Animal Healthcare Business was sold on 30th September 2015. Hence, for comparison purpose only, Financials for the Animal Healthcare Business are not considered for Quarter Ended 30th September 2015.*

About Lyka Labs Limited

Lyka Labs Limited (BSE-LYKALABS/500259: NSE-LYKALABS) is a leading pharmaceutical company with strong capabilities in Sterile Preparations and Dermatology. It has a wide portfolio of 20+ Lyophilized Products and 50+ products in Dermatology. Its products are marketed across 46 markets globally. From its R&D Centre in Mumbai, Lyka is currently working on development of a wide range of New Formulations and New Drug Delivery System in its focus areas of Lyophilization and Dermatology and has a portfolio of over 20 products under development

For Queries, Please Contact

Lyka Labs Limited

Yogesh Shah

Chief Financial Officer

Tel: +91 22 66112200

ybshah@lykalabs.com

Piyush Hindia

Company Secretary

Tel: +91 22 66112200

companysecretary@lykalabs.com

Registered Office

Lyka Labs Limited

4801/B & 4802/A

G.I.D.C. Industrial Estate,

Ankleshwar – 393 002

Corporate Information

BSE Code: 500259

NSE Code: LYKALABS

Website: www.lykalabs.com

CIN: L24230GJ1976PLC008738

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Sequent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances